News & Events

Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium

Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium

Groningen, the Netherlands – November 10, 2014 – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at the 9th International Respiratory Syncytial Virus Symposium (RSV2014), taking place in Stellenbosch, South Africa from 9-13 November.

SynGEM® uses Mucosis’s proprietary Mimopath® platform to activate mucosal defenses, allowing more effective protection against infectious diseases. The data to be presented will include updates on the development of Mucosis’s unique stable prefusion form of the F vaccine antigen, which is particularly effective against RSV due to the powerful virus neutralizing antibodies it elicits. Results from preclinical studies of SynGEM® in animal models will also be included.

Dr. Kees Leenhouts, Chief Scientific Officer of Mucosis said, “There is increasing evidence that mucosal immunity is key for protection against RSV infection, which is a global health challenge. These data demonstrate that our intranasal RSV vaccine lead product, SynGEM®, effectively elicits robust and durable mucosal immunity in addition to providing systemic immunity. Our unique and stable prefusion F form of the antigen can raise more potent neutralizing antibodies against RSV compared with a postfusion F antigen. These data demonstrate the vaccine’s immunogenicity, efficacy and safety in animal models, and support the prophylactic potential of SynGEM® across target age groups. These results further validate the potential clinical value of our unique intranasal approach and the utility of the proprietary prefusion-like F form of the antigen we have developed.”

Thomas Johnston, Chief Executive Officer of Mucosis commented, “RSV2014 is a further opportunity to present the strong evidence behind the breakthroughs we are making in preventing serious infectious diseases. Our advances in both the efficacy and capacity for high-yield manufacturing of RSV vaccines continue to set Mucosis apart in this competitive market.”

“SynGEM®: An intranasal prefusion-like RSV F subunit vaccine,” by Bert Jan Haijema, Maarten van Roosmalen, Ivy Widjaja, Alan Rigter of Mucosis, Xander de Haan, Peter Rottier of Utrecht University and Kees Leenhouts, will be presented by Dr. Haijema, at RSV2014 on November 11 from 16:30-18:00 in the “Novel RSV vaccine approaches” category, at poster 37.

About Mucosis

Mucosis B.V. (Mucosis) is a clinical-stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases. Mucosis’s investigational patient-friendly vaccines can be delivered via the nose or mouth to elicit a more natural immune response with a broader base of protection. The company is developing multiple programs for its clinical-stage proprietary Mimopath® platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body.

Mucosis’s lead product SynGEM®, a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection, will enter human proof-of-concept studies in 2016. The annual global burden of RSV illness is significant, with 33.8 million estimated new episodes of RSV-associated acute lower respiratory infection (ALRI) worldwide in children under 5, and over 3.4 million hospital admissions associated with severe RSV disease. Global mortality was estimated at 253,500 deaths in 2010.

The company has also developed PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM®, a vaccine against influenza. FluGEM® served as a successful proof of concept for the Mimopath® platform in human clinical testing.

Mucosis has raised over EUR 20m, with key investment partners including MedSciences, BioGeneration, NOM & UU Holdings. The company has strategic partnerships in US, Asia and the EU with organisations including the US National Institutes of Health, China-based Changchun BCHT Biotechnology co., and the Netherlands Enterprise Agency. Mucosis’s management is highly experienced in the design, development and commercialisation of vaccines. Mucosis employs over 10 staff at its headquarters in Groningen, The Netherlands.

About RSV2014

RSV2014 is a three and a half day international meeting of the RSV scientific community with a programme covering a broad range of topics, with many highlights including the recent advances in vaccine development.

Issued for and on behalf of Mucosis by Instinctif Partners.

For more information please contact

back to news